Pharma Mar, S.A. PHM.MC Stock
Pharma Mar, S.A. Price Chart
Pharma Mar, S.A. PHM.MC Financial and Trading Overview
| Pharma Mar, S.A. stock price | 27.72 EUR |
| Previous Close | 33.04 EUR |
| Open | 33.2 EUR |
| Bid | 33.42 EUR x 0 |
| Ask | 33.58 EUR x 0 |
| Day's Range | 33.12 - 33.78 EUR |
| 52 Week Range | 32.02 - 74.86 EUR |
| Volume | 18.01K EUR |
| Avg. Volume | 61.24K EUR |
| Market Cap | 603.49M EUR |
| Beta (5Y Monthly) | 0.094252 |
| PE Ratio (TTM) | 20.987501 |
| EPS (TTM) | 0.06 EUR |
| Forward Dividend & Yield | 0.65 (1.95%) |
| Ex-Dividend Date | June 7, 2023 |
| 1y Target Est | 76.34 EUR |
PHM.MC Valuation Measures
| Enterprise Value | 457.45M EUR |
| Trailing P/E | 20.987501 |
| Forward P/E | 9.100271 |
| PEG Ratio (5 yr expected) | 0.43 |
| Price/Sales (ttm) | 3.4069095 |
| Price/Book (mrq) | 2.727199 |
| Enterprise Value/Revenue | 2.582 |
| Enterprise Value/EBITDA | 19.795 |
Trading Information
Pharma Mar, S.A. Stock Price History
| Beta (5Y Monthly) | 0.094252 |
| 52-Week Change | -46.69% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 74.86 EUR |
| 52 Week Low | 32.02 EUR |
| 50-Day Moving Average | 37 EUR |
| 200-Day Moving Average | 53.46 EUR |
PHM.MC Share Statistics
| Avg. Volume (3 month) | 61.24K EUR |
| Avg. Daily Volume (10-Days) | 78.33K EUR |
| Shares Outstanding | 17.97M |
| Float | 14.07M |
| Short Ratio | N/A |
| % Held by Insiders | 21.94% |
| % Held by Institutions | 11.36% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.65 |
| Trailing Annual Dividend Yield | 1.96% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.40919998 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 16.25% |
| Operating Margin (ttm) | 11.56% |
| Gross Margin | 93.23% |
| EBITDA Margin | 13.04% |
Management Effectiveness
| Return on Assets (ttm) | 3.40% |
| Return on Equity (ttm) | 13.75% |
Income Statement
| Revenue (ttm) | 177.14M EUR |
| Revenue Per Share (ttm) | 10.88 EUR |
| Quarterly Revenue Growth (yoy) | -36.10% |
| Gross Profit (ttm) | 182.7M EUR |
| EBITDA | 23.11M EUR |
| Net Income Avi to Common (ttm) | 28.79M EUR |
| Diluted EPS (ttm) | 1.6 |
| Quarterly Earnings Growth (yoy) | -93.60% |
Balance Sheet
| Total Cash (mrq) | 183.13M EUR |
| Total Cash Per Share (mrq) | 10.11 EUR |
| Total Debt (mrq) | 43.39M EUR |
| Total Debt/Equity (mrq) | 20 EUR |
| Current Ratio (mrq) | 2.892 |
| Book Value Per Share (mrq) | 12.313 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Pharma Mar, S.A.
| Country | Spain |
| State | N/A |
| City | Madrid |
| Address | Avenida de los Reyes, 1 |
| ZIP | 28770 |
| Phone | 34 91 846 60 00 |
| Website | https://www.pharmamar.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 515 |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Q&A For Pharma Mar, S.A. Stock
What is a current PHM.MC stock price?
Pharma Mar, S.A. PHM.MC stock price today per share is 27.72 EUR.
How to purchase Pharma Mar, S.A. stock?
You can buy PHM.MC shares on the MCE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharma Mar, S.A.?
The stock symbol or ticker of Pharma Mar, S.A. is PHM.MC.
Which industry does the Pharma Mar, S.A. company belong to?
The Pharma Mar, S.A. industry is Biotechnology.
How many shares does Pharma Mar, S.A. have in circulation?
The max supply of Pharma Mar, S.A. shares is 17.51M.
What is Pharma Mar, S.A. Price to Earnings Ratio (PE Ratio)?
Pharma Mar, S.A. PE Ratio is 462.00000000 now.
What was Pharma Mar, S.A. earnings per share over the trailing 12 months (TTM)?
Pharma Mar, S.A. EPS is 0.06 EUR over the trailing 12 months.
Which sector does the Pharma Mar, S.A. company belong to?
The Pharma Mar, S.A. sector is Healthcare.
Pharma Mar, S.A. PHM.MC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| IBEX 35 IBEX | 13.12 EUR 11681.24 USD |
-1.43
|
7.57K EUR 168.4M USD | 10661 EUR 11653.91 USD | 10780.9 EUR 11784.98 USD | — - | 7.57K EUR 168.4M USD |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}